As all eyes are on Takeda these days after its announced acquisition of Shire, Jon Neal, managing director of the UK and Ireland operations of the Japanese player, looks back on the company’s internationalisation path. He further highlights the extremely collaborative approach Takeda engages in with NICE and gives tips for successful HTA approval processes.
You have just joined as director of the UK and Ireland operations after spending several years with the company. Given the exciting context we are currently in, what priorities were laid out for your tenure?
"Our goal at Takeda is to be the most respected company in each of the therapeutic areas in which we are active, to be competitive, but also to be valued both by our customers and our employees."
